

JARC Pilot study Toronto guidelines Working Group

Belgium: Belgium National CR (Liesbet Van Eycken, Nancy Van Damme);

Denmark: National CR (Filippa Nyboe Norsker, Jeanette Falck Winther);

Estonia: National CR (Kaire Innos, Keiu Paapsi);

France: National Childhood CR of Solid Tumours (Brigitte Lacour, Emmanuel Desandes);

Greece: University of Athens (Eleni Petridou);

Germany: German Childhood CR (Claudia Spix);

Hungary: Hungarian Childhood CR (Jakab Zsuzsanna);

Italy: Agrigento and Trapani CR (Pina Candela, Tiziana Scuderi), Barletta Andria Trani CR (Enzo Coviello), Campania Childhood CR (Francesco Vetrano, Fabio Savoia), Catania Siracusa Enna CR (Marine Castaing), Palermo CR (Francesco Vitale, Rosalba Amodio), Pavia CR (Lorenza Boschetti), Varese CR (Giovanna Tagliabue, Sabrina Fabiano);

Malta: National CR (Dominic Agius);

Norway: National CR (Bernward Zeller);

Portugal: South Portugal CR (Ana Miranda, Gabriela Caldas);

Slovakia: National CR (Chakameh Safaei Diba);

Slovenia: National CR (Zadnik Vesna);

Spain: Basque Country CR (Arantza Lopez de Munain Marques), Girona childhood CR (Rafael Marcos-Gragera), Granada CR (Maria José Sánchez Pérez), Murcia CR (Maria Dolores Chirlaque), Navarra CR (Eva Ardanaz, Marcela del Pilar), Spanish Registry of Childhood Tumours (RETI-SEHOP), University of Valencia (Rafael Peris Bonet);

Switzerland: Switzerland Childhood CR (Claudia Kühni, Shelagh Redmond);

TABLE S1: Summary of the staging system in the Toronto Guidelines[6] for Neuroblastoma and Wilms tumours

Tumour	Staging system	Tier 2 stage category, summary definition		Tier 1 stage category, summary definition
Neuroblastoma	INRG [18]	L1	localized tumour that does not involve any vital structures as defined by the list of IDRFs and the tumour must be confined within one body compartment (neck, chest, abdomen, or pelvis)	L , Localised not involving vital structures confined to one body compartement
		L2	locoregional tumour with one or more IDRFs	LR , Locoregional tumour with spread
		MS	metastatic disease confined to skin, liver, and/or bone marrow, in a patients less than 18 months old	MS
		M	distant metastatic diseases (not contiguous with the primary tumour) except as defined for stage MS	M , Metastatic distant metastatic disease (excluding MS)
Wilms tumour	COG/NWTSG [7]	I	tumour limited to kidney and completely resected	Localised , tumour confined to area of origin
		II	tumour extends beyond kidney but completely resected	
		III	residual tumour or non-haematogenous mestases confined to abdomen	
		IV	haematogenous metastases or spread beyond abdomen at diagnosis	Metastatic , distant metastases present at diagnosis
	SIOP [7]	yI	tumour limited to kidney and completely resected	Localised , tumour confined to area of origin
		yII	tumour extends beyond kidney but completely resected	
		yIII	Incomplete excision of the tumour (gross or microscopic extension beyond the resection margins)	
		IV	haematogenous metastases or spread beyond abdomen at diagnosis	Metastatic , distant metastases present at diagnosis

COG=Children's Oncology Group; IDREFs=image defined risk factors; NWTSG=National Wilms Tumour Study Group; SIOP=International Society of Paediatric Oncology

Neuroblastoma ICCC-3 IVa; ICD-O-3 morphology code: 9490, 9500, topography code C000-C809

Wilms tumour ICCC-3 VIa1; ICD-O-3 morphology code: 8959, 8960, topography code C649

Table S2: Comparison of stage distribution and survival between our study and clinical studies

		Stage				
		I/yI	II/yII	III/yIII	IV	Total
Wilms tumours						
JARC pilot	number	185	99	90	59	433
	%	43%	23%	21%	13%	100%
	3-yr survival %	97	98	88	77	93
SIOP WT2001database (2001-2015) ¹						
	number	1610	746	678	525	3559
	%	45%	21%	19%	15%	100%
	5-yr survival %	98	94	90	82	93
Neuroblastoma		L1	L2			
JARC pilot	number	128	110			
	%	54%	46%			
	3-yr survival %	99	92			
SIOPEN ²	number	332	329			
	%	50%	50%			
	5-yr survival %	96	89			

1. Brok J, Pritchard-Jones K, Geller JI, Spreafico F. Review of phase I and II trials for WT – Can we optimise the search for novel agents? EJC 79 (2017) 205-213.
2. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force. The International neuroblastoma risk group (INRG) staging system: an INRG task force report, J Clin Oncol 27(2009) 298–303.